Dr. Kutzkey is a founding member and Chair of the Nura Bio board of directors. He is Managing Partner, The Column Group (TCG), which he joined in 2007 shortly after the firm’s inception. He has since played an active role in the launch of more than a dozen of the firm’s portfolio companies. His primary focus is company creation, often taking interim management roles at new start-ups until the recruitment of a permanent leadership team. Dr. Kutzkey has served as the acting CEO of Nurix Therapeutics, Peloton Therapeutics, Neurona Therapeutics, Surrozen and Nura Bio. Dr. Kutzkey was formerly a scientist at KAI Pharmaceuticals, focused on the discovery and development of selective protein kinase C inhibitors. Prior to KAI, he attended UC Berkeley as a graduate student in the lab of Dr. Robert Tjian, completing his PhD in 2005. Dr. Kutzkey earned his undergraduate degree at Stanford University.